The shares of SVMK Inc. (NASDAQ:SVMK) has been pegged with a rating of Buy by UBS in its latest research note that was published on August 2nd, 2019. The research company has also assigned a $24 price target. UBS wasn’t the only research firm that published a report of SVMK Inc., with other equities research analysts also giving their opinion on the stock. SunTrust advised investors in its research note published on June 10th, 2019, to Buy the SVMK stock while also putting a $22 price target. The stock had earned Overweight rating from Stephens when it published its report on March 22nd, 2019. The stock was given Market Perform rating by Wells Fargo in its report released on November 13th, 2018, the day when the price target on the stock was placed at $13. SunTrust was of a view that SVMK is Buy in its latest report on October 22nd, 2018 while giving it a price target of $16. JP Morgan thinks that SVMK is worth Overweight rating. This was contained in the firm’s report on October 22nd, 2018 in which the stock’s price target was also moved to $15.
The consensus currently stands at a Hold while its average price target is $21.57. The price of the stock the last time has raised by 78.81% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 52.19.
The shares of the company dipped by -2.28% during the trading session on Tuesday, reaching a low of $17.47 while ending the day at $17.97. During the trading session, a total of 2.16 million shares were traded which represents a -20.95% decline from the average session volume which is 1.79M shares. SVMK had ended its last session trading at 18.39. SVMK Inc. currently has a market cap of $2.37B while its P/E earnings growth sits at 8.58. SVMK Inc. debt-to-equity ratio currently stands at 0.75, while its quick ratio hovers at 1.10. SVMK 52-week low price stands at $10.05 while its 52-week high price is $20.00.
SVMK Inc. has the potential to record -1.48 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Needham published a research note on August 8th, 2019 where it informed investors and clients that Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) is now rated as Buy. Their price target on the stock stands at $54. SunTrust also rated AERI as Reiterated on June 10th, 2019, with its price target of $22 suggesting that AERI could surge by 61.37% from its current share price. Even though the stock has been trading at $24.21/share, analysts expect it to surge higher by 0.70% to reach $63.11/share. It started the day trading at $25.76 and traded between $23.82 and $24.38 throughout the trading session.
A look at its technical shows that AERI’s 50-day SMA is 27.14 while its 200-day SMA stands at 38.93. At the moment, only of Aerie Pharmaceuticals, Inc. shares were sold short. The company’s average trading volume currently stands at 777.20K shares, which means that the short-interest ratio is just 7.33 days. Over the past seven days, the company moved, with its shift of 12.45%. Looking further, the stock has dropped -40.11% over the past 90 days while it lost -41.59% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. Wellington Management Co LLP bought more AERI shares, increasing its portfolio by +1.05% during the last quarter. This move now sees Wellington Management Co LLP purchasing 65,861 shares in the last quarter, thus it now holds 6,318,560 shares of AERI, with a total valuation of $136,923,195. The Vanguard Group Inc meanwhile bought more AERI shares in the recently filed quarter, changing its stake to $87,355,866 worth of shares. Deerfield Management Company LP followed the path by increasing its AERI portfolio by +82.31% in the quarter. This means that Deerfield Management Company LP bought 1,324,202 shares in the last quarter and now controls 2,932,987 shares of the AERI stock, with the valuation hitting $63,557,828.
Similarly, Adage Capital Management LP decreased its Aerie Pharmaceuticals, Inc. shares by -28.30% during the recently filed quarter. Following these latest developments, around 1.70% of Aerie Pharmaceuticals, Inc. stocks are owned by institutional investors and hedge funds.